Evidence map›Paper›PMID 36722977›Full record

ArticleInfection and immunity2023

The Impact of Colistin Resistance on the Activation of Innate Immunity by Lipopolysaccharide Modification.

José Avendaño-Ortiz, Manuel Ponce-Alonso, Emilio Llanos-González, Hugo Barragán-Prada, Raquel Barbero-Herranz, Roberto Lozano-Rodríguez, Francesc J Márquez-Garrido, José María Hernández-Pérez, María-Isabel Morosini, Rafael Cantón and 2 more

Open access · greenAbstract read
In one paragraph

Article in Infection and immunity, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Lipid A modification of colistin-resistantInfection and immunity · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

José Avendaño-Ortiz *Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.ORCID 0000-0003-2774-1821
Manuel Ponce-Alonso *Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.ORCID 0000-0002-3239-9373
Emilio Llanos-GonzálezDepartamento de Ciencias Médicas, Facultad de Medicina, Universidad de Castilla-La Mancha, Ciudad Real, Spain.ORCID 0000-0001-9449-2226
Hugo Barragán-PradaServicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
Raquel Barbero-HerranzServicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
Roberto Lozano-RodríguezGrupo Respuesta Inmune Innata, IdiPAZ, Hospital Universitario de la Paz, Madrid, Spain.ORCID 0000-0003-0093-9707
Francesc J Márquez-GarridoBruker Española S.A., Madrid, Spain.
José María Hernández-PérezInstituto de Investigación Germans Trias i Pujol, Badalona, Spain.
María-Isabel MorosiniServicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
Rafael CantónServicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.ORCID 0000-0003-1675-3173
Rosa Del CampoServicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.ORCID 0000-0003-1147-7923
Eduardo López-CollazoGrupo Respuesta Inmune Innata, IdiPAZ, Hospital Universitario de la Paz, Madrid, Spain.ORCID 0000-0003-1957-877X
Instituto de Salud Carlos III · ESHospital Universitario La Paz · ESInstitut d'Investigació en Ciències de la Salut Germans Trias i Pujol · ESUniversity of Castilla-La Mancha · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colistin resistance is acquired by different lipopolysaccharide (LPS) modifications. We proposed to evaluate the of effect

Indexed as

ColistinKlebsiella InfectionsAnti-Bacterial AgentsBacterial ProteinsCytokinesDrug Resistance, BacterialHumansImmunity, InnateKlebsiella pneumoniaeLipopolysaccharidesMicrobial Sensitivity TestsAnti-Bacterial AgentsBacterial ProteinsColistinCytokinesLipopolysaccharidesantibiotic resistancecolistinimmune checkpointsinflammationLPS modificationmonocytesphagocytosis

Identifiers

PMID36722977
PMCPMC9933656
OpenAlexW4318754283

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.